Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma

Our aim was to evaluate the prognostic role of the pretreatment serum albumin level in patients with malignant pleural mesothelioma (MPM) receiving platinum-based systemic chemotherapy. From 1995 to 2013, a total of 97 patients receiving platinum-based systemic chemotherapy for newly diagnosed MPM w...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2014-07, Vol.35 (7), p.6839-6845
Main Authors: Yao, Zhou-Hong, Tian, Guang-Yan, Yang, Shao-Xiang, Wan, Yun-Yan, Kang, Yan-Meng, Liu, Qing-Hua, Yao, Fei, Lin, Dian-Jie
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers
Biomarkers, Pharmacological - metabolism
Biomedical and Life Sciences
Biomedicine
Cancer Research
Female
Humans
Lung cancer
Lung Neoplasms - blood
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Medical prognosis
Mesothelioma - blood
Mesothelioma - drug therapy
Mesothelioma - pathology
Mesothelioma, Malignant
Middle Aged
Platinum - therapeutic use
Pleural Neoplasms - blood
Pleural Neoplasms - drug therapy
Pleural Neoplasms - pathology
Prognosis
Proportional Hazards Models
Proteins
Research Article
Serum Albumin - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Our aim was to evaluate the prognostic role of the pretreatment serum albumin level in patients with malignant pleural mesothelioma (MPM) receiving platinum-based systemic chemotherapy. From 1995 to 2013, a total of 97 patients receiving platinum-based systemic chemotherapy for newly diagnosed MPM were enrolled. All clinical information and laboratory results were retrospectively collected from the medical records. The Kaplan–Meier method was used to calculate survival. The Cox proportional hazards model was used to identify significant independent prognostic factors for predicting survival. In total, 34 of the 97 patients (35.1 %) had hypoalbuminaemia (albumin ≤35 g/l). The 1-year overall survival rate was 44.1 % for patients with hypoalbuminaemia and 72.0 % for patients with a normal albumin level. Multivariate analysis indicated that pretreatment albumin was an independent prognostic factor in MPM. Patients with hypoalbuminaemia had a greater risk of death than those with a normal albumin level [hazard ratio (HR) 1.778; 95 % confidence interval (CI) 1.504–2.998; P  = 0.031]. When albumin was entered as a continuous variable in the Cox regression model, the HR of death was significantly decreased by 9.8 % (95 % CI 0.851–0.956) for each 1-g/l increment. The pretreatment serum albumin level is a simple, inexpensive and easily measurable marker with prognostic significance in MPM patients treated with platinum-based systemic chemotherapy.
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-014-1938-5